AZTA

Azenta, Inc.

A life sciences company that helps researchers around the world store, manage, and analyze biological samples. Its automated ultra-cold freezers, sample tubes and vials, lab software, and cold-chain logistics keep everything from clinical-trial specimens to blood samples safe, while its GENEWIZ brand provides gene sequencing and DNA synthesis services. Founded in 1978 in Massachusetts as Brooks Automation, it spent decades building robots for making semiconductors before pivoting to biological samples and renaming itself Azenta in late 2021. Fittingly, the same robotics know-how that once handled delicate silicon wafers now gently shuffles frozen vials in automated freezers—an unexpected turn from chips to cells.

CUSIP: 114340102HealthcareUS1 holder

Ownership Activity Financials Filings

Insiders

Ranked by how much each holding moved in the last 3 years

Insider

Koffey QuentinDirector · 3 transactions

4.62M—

Granted 10.7K

Schwartz Stephen SCEO, Director · 3 transactions

446.5K+6.2%

as of Nov 2023

Granted 38.9K

Marotta JohnPresident and CEO, Director · 10 transactions

213.2K—

Granted 210.5K · Bought 15.0K · Sold 316

Robertson Lindon GEVP & Chief Financial Officer · 2 transactions

121.1K+3%

as of Nov 2023

Granted 6.3K

Joseph JasonSVP, General Counsel, Secy. · 13 transactions

112.6K+12.8%

as of Nov 2024

Granted 33.8K · Sold 1.1K

Lin Lawrence Y.EVP, CFO and Treasurer · 7 transactions

79.7K—

Granted 73.7K

Gray David CChief Strategy & New Business · 4 transactions

74.9K+6%

as of Nov 2023

Granted 5.2K

Starr EphraimSVP, Gen Counsel & Secretary · 3 transactions

68.4K—

Granted 72.0K

Cornog William LDirector · 6 transactions

45.5K—

Bought 29.5K

Zhou GingerSVP and GM, Multiomics · 12 transactions

38.8K+337%

Granted 32.6K · Bought 417 · Sold 1.6K

Davis Robyn CDirector · 2 transactions

33.6K+24%

as of Feb 2025

Granted 6.5K

Pirogova OlgaSVP and CHRO · 7 transactions

33.0K—

Granted 36.2K · Sold 1.6K

Vacha RobinSVP, GM Life Science Products · 6 transactions

31.3K+24.1%

as of Feb 2024

Granted 9.2K

Wang David DongSVP & GM, SMS · 6 transactions

24.0K—

as of Dec 2024

Granted 18.2K · Sold 348

Cueto HermanEVP, Chief Financial Officer · 5 transactions

23.9K—

as of Nov 2024

Granted 26.2K · Sold 2.3K

McLaughlin EricaDirector · 3 transactions

22.5K+117.5%

Granted 12.2K

Casal FrankDirector · 3 transactions

21.8K+276.6%

Granted 16.0K

Martin William E. IIIPresident Multiomics · 1 transaction

17.8K—

Granted 17.8K

Malus Alan JDirector · 3 transactions

17.0K—

as of May 2025

Granted 4.0K · Bought 12.0K

Nova Tina SusanDirector · 3 transactions

15.8K+337.6%

Granted 12.2K

Rosenblatt MichaelDirector · 1 transaction

13.0K+23.3%

as of Feb 2024

Granted 2.5K

Doshi DipalDirector · 2 transactions

9.7K—

Granted 9.7K

Hughes ViolettaVP, Chief Accounting Officer · 6 transactions

9.6K—

as of Feb 2025

Granted 8.6K · Sold 480

Madaus Martin DDirector · 2 transactions

7.4K—

as of Nov 2024

Granted 2.5K · Bought 4.9K

Hirsch DidierDirector · 2 transactions

3.5K—

as of Nov 2024

Granted 2.5K · Bought 1.0K

Bousa Edward PeterDirector · 1 transaction

2.5K—

as of Feb 2024

Granted 2.5K

Insider	Stake change	Holds now	Granted / vested	Bought	Sold
Koffey QuentinDirector · 3 transactions	—	4.62M	10.7K	—	—
Schwartz Stephen SCEO, Director · 3 transactions	+6.2%	446.5Kas of Nov 2023	38.9K	—	—
Marotta JohnPresident and CEO, Director · 10 transactions	—	213.2K	210.5K	15.0K	316
Robertson Lindon GEVP & Chief Financial Officer · 2 transactions	+3%	121.1Kas of Nov 2023	6.3K	—	—
Joseph JasonSVP, General Counsel, Secy. · 13 transactions	+12.8%	112.6Kas of Nov 2024	33.8K	—	1.1K
Lin Lawrence Y.EVP, CFO and Treasurer · 7 transactions	—	79.7K	73.7K	—	—
Gray David CChief Strategy & New Business · 4 transactions	+6%	74.9Kas of Nov 2023	5.2K	—	—
Starr EphraimSVP, Gen Counsel & Secretary · 3 transactions	—	68.4K	72.0K	—	—
Cornog William LDirector · 6 transactions	—	45.5K	—	29.5K	—
Zhou GingerSVP and GM, Multiomics · 12 transactions	+337%	38.8K	32.6K	417	1.6K
Davis Robyn CDirector · 2 transactions	+24%	33.6Kas of Feb 2025	6.5K	—	—
Pirogova OlgaSVP and CHRO · 7 transactions	—	33.0K	36.2K	—	1.6K
Vacha RobinSVP, GM Life Science Products · 6 transactions	+24.1%	31.3Kas of Feb 2024	9.2K	—	—
Wang David DongSVP & GM, SMS · 6 transactions	—	24.0Kas of Dec 2024	18.2K	—	348
Cueto HermanEVP, Chief Financial Officer · 5 transactions	—	23.9Kas of Nov 2024	26.2K	—	2.3K
McLaughlin EricaDirector · 3 transactions	+117.5%	22.5K	12.2K	—	—
Casal FrankDirector · 3 transactions	+276.6%	21.8K	16.0K	—	—
Martin William E. IIIPresident Multiomics · 1 transaction	—	17.8K	17.8K	—	—
Malus Alan JDirector · 3 transactions	—	17.0Kas of May 2025	4.0K	12.0K	—
Nova Tina SusanDirector · 3 transactions	+337.6%	15.8K	12.2K	—	—
Rosenblatt MichaelDirector · 1 transaction	+23.3%	13.0Kas of Feb 2024	2.5K	—	—
Doshi DipalDirector · 2 transactions	—	9.7K	9.7K	—	—
Hughes ViolettaVP, Chief Accounting Officer · 6 transactions	—	9.6Kas of Feb 2025	8.6K	—	480
Madaus Martin DDirector · 2 transactions	—	7.4Kas of Nov 2024	2.5K	4.9K	—
Hirsch DidierDirector · 2 transactions	—	3.5Kas of Nov 2024	2.5K	1.0K	—
Bousa Edward PeterDirector · 1 transaction	—	2.5Kas of Feb 2024	2.5K	—	—

Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.